Effect of Sapanisertib (MLN0128) on the QTc Interval in Participants With Advanced Solid Tumors

NCT02197572 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

44

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors

Interventions

DRUG: Sapanisertib

Sponsor

Calithera Biosciences, Inc